297 related articles for article (PubMed ID: 25437539)
41. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Ambati SR; Shieh JH; Pera B; Lopes EC; Chaudhry A; Wong EW; Saxena A; Su TL; Moore MA
Oncotarget; 2016 Jul; 7(28):43062-43075. PubMed ID: 27248664
[TBL] [Abstract][Full Text] [Related]
42. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.
Boulton S; Pemberton LC; Porteous JK; Curtin NJ; Griffin RJ; Golding BT; Durkacz BW
Br J Cancer; 1995 Oct; 72(4):849-56. PubMed ID: 7547230
[TBL] [Abstract][Full Text] [Related]
43. Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
McPherson LA; Shen Y; Ford JM
Cancer Lett; 2014 Feb; 343(2):217-23. PubMed ID: 24215868
[TBL] [Abstract][Full Text] [Related]
44. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
45. Irinotecan dose schedule for the treatment of Ewing sarcoma.
Slotkin EK; Meyers PA
Pediatr Blood Cancer; 2023 Jan; 70(1):e30005. PubMed ID: 36184748
[TBL] [Abstract][Full Text] [Related]
46. Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response.
Cristalli C; Manara MC; Valente S; Pellegrini E; Bavelloni A; De Feo A; Blalock W; Di Bello E; Piñeyro D; Merkel A; Esteller M; Tirado OM; Mai A; Scotlandi K
Front Endocrinol (Lausanne); 2022; 13():876602. PubMed ID: 35712255
[TBL] [Abstract][Full Text] [Related]
47. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
[TBL] [Abstract][Full Text] [Related]
48. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.
Vormoor B; Schlosser YT; Blair H; Sharma A; Wilkinson S; Newell DR; Curtin N
Oncotarget; 2017 Dec; 8(69):113418-113430. PubMed ID: 29371919
[TBL] [Abstract][Full Text] [Related]
49. New strategies in ewing sarcoma: lost in translation?
Arnaldez FI; Helman LJ
Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
[TBL] [Abstract][Full Text] [Related]
50. Nanoparticle-mediated measurement of target-drug binding in cancer cells.
Ullal AV; Reiner T; Yang KS; Gorbatov R; Min C; Issadore D; Lee H; Weissleder R
ACS Nano; 2011 Nov; 5(11):9216-24. PubMed ID: 21962084
[TBL] [Abstract][Full Text] [Related]
51. Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Zhai B; Li Y; Kotapalli SS; Bacha J; Brown D; Steinø A; Daugaard M
Cell Death Dis; 2020 Jul; 11(7):577. PubMed ID: 32709853
[TBL] [Abstract][Full Text] [Related]
52. Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.
Thurber GM; Reiner T; Yang KS; Kohler RH; Weissleder R
Mol Cancer Ther; 2014 Apr; 13(4):986-95. PubMed ID: 24552776
[TBL] [Abstract][Full Text] [Related]
53. Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.
Wagner L
Sarcoma; 2011; 2011():957957. PubMed ID: 21512587
[TBL] [Abstract][Full Text] [Related]
54. Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Wagner LM
Clin Sarcoma Res; 2015; 5():20. PubMed ID: 26322224
[TBL] [Abstract][Full Text] [Related]
55. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
[TBL] [Abstract][Full Text] [Related]
56. Orthotopic patient-derived xenografts of paediatric solid tumours.
Stewart E; Federico SM; Chen X; Shelat AA; Bradley C; Gordon B; Karlstrom A; Twarog NR; Clay MR; Bahrami A; Freeman BB; Xu B; Zhou X; Wu J; Honnell V; Ocarz M; Blankenship K; Dapper J; Mardis ER; Wilson RK; Downing J; Zhang J; Easton J; Pappo A; Dyer MA
Nature; 2017 Sep; 549(7670):96-100. PubMed ID: 28854174
[TBL] [Abstract][Full Text] [Related]
57. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
[TBL] [Abstract][Full Text] [Related]
58. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
[TBL] [Abstract][Full Text] [Related]
59. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
60. RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.
Erkizan HV; Schneider JA; Sajwan K; Graham GT; Griffin B; Chasovskikh S; Youbi SE; Kallarakal A; Chruszcz M; Padmanabhan R; Casey JL; Üren A; Toretsky JA
Nucleic Acids Res; 2015 Jan; 43(2):1069-80. PubMed ID: 25564528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
